MINK THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9275 USD | +6.46% |
|
+5.84% | -13.32% |
| Mar. 21 | Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
| Mar. 21 | MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Presenter SpeechJennifer Buell (Executives)Good afternoon, everyone, and thank you for sharing...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9275
USD
Average target price
8
USD
Spread / Average Target
+762.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.32% | 32.18M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- INKT Stock
- News MiNK Therapeutics, Inc.
- Transcript : MiNK Therapeutics, Inc. - Special Call
